atazanavir + lamivudine + tenofovir disoproxil fumarate

This is a three-drug antiretroviral combination used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It consists of: - **Atazanavir**: a protease inhibitor that blocks the HIV protease enzyme, preventing viral replication. - **Lamivudine**: a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits reverse transcriptase, an enzyme necessary for viral DNA synthesis. - **Tenofovir disoproxil fumarate**: a nucleotide reverse transcriptase inhibitor (NtRTI), also inhibiting reverse transcriptase and blocking HIV replication. The combination is typically used as part of highly active antiretroviral therapy (HAART). Atazanavir may be administered unboosted or with ritonavir; however, when combined with tenofovir disoproxil fumarate, boosting with ritonavir is generally recommended to maintain adequate atazanavir plasma concentrations[1][4]. This regimen helps achieve virological suppression in patients with HIV and is indicated for use in adults and pediatric patients weighing at least 35 kg when combined with other antiretrovirals[4][6].

Other names

atazanavir plus lamivudine plus tenofovir disoproxil fumarate